Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 3/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17625618 | 0.79 | KMT2A (0.41) | ALDH1A1KMT2AMAPTMEN1POLB | |
| SCHEMBL17625220 | 0.76 | SIGMAR1 (0.49) | ALDH1A1KMT2AMAPTMEN1SIGMAR1 | |
| SCHEMBL17625219 | 0.75 | SIGMAR1 (0.48) | ALDH1A1KMT2AMAPTMEN1PKM | |
| SCHEMBL16202782 | 0.70 | SIGMAR1 (0.44) | ALDH1A1KMT2AMAPTMEN1SIGMAR1 | |
| SCHEMBL28349002 | 0.70 | MAPT (0.51) | ALDH1A1KMT2AMAPTMEN1PKM | |
| SCHEMBL17625617 | 0.67 | MAPT (0.35) | ALDH1A1KMT2AMAPTMEN1SIGMAR1 | |
| SCHEMBL19039519 | 0.66 | MAPT (0.45) | ALDH1A1KMT2AMAPTMEN1SIGMAR1 | |
| SCHEMBL17625616 | 0.64 | SIGMAR1 (0.35) | KMT2AMAPTMEN1SIGMAR1 | |
| SCHEMBL14337468 | 0.64 | SIGMAR1 (0.64) | ALDH1A1KMT2AMAPTMEN1SIGMAR1 | |
| SCHEMBL22025141 | 0.63 | MAPT (0.42) | ALDH1A1KMT2AMAPTMEN1PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160087295-A1 | Catalyst and Process for the Production of Hydrogen from Ammonia Boranes | UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN (IE) | 2016-03-24 | — | — | US | disclosed |
| US-20160087295-A1 | Catalyst and Process for the Production of Hydrogen from Ammonia Boranes | UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN (IE) | 2016-03-24 | — | — | US | disclosed |
| WO-2014174465-A2 | PROCESS | NOVAUCD (IE) | 2014-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160087295-A1 | Catalyst and Process for the Production of Hydrogen from Ammonia Boranes | HRH4, NR1H3, NR1H2 | ALDH1A1 3835/4885KMT2A 2731/4885MAPT 4863/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.